Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00822679 · ClinicalTrials.gov registry record · Phase 4
Eszopiclone and Inflammatory Mediators in Patients With Acute Coronary Syndrome
A Phase 4 study, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT00822679: Completed Phase 4 study, sponsored by University of Arizona.
NCT00822679 is a Phase 4 study that has completed, run by University of Arizona. The registered enrollment target is 5 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00822679, a Phase 4 study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of the study is to examine the effects of Eszopiclone, a sleep aid, on inflammatory mediators and coagulability in patients with a recent myocardial infarction.
Primary Outcome
Not performed. Zero subjects were randomized. Many potential participants screen-failed.
Interventions
- OTHER Placebo
- DRUG Eszopiclone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-01 |
| Phase | Phase 4 |
What the finished NCT00822679 record still lists
NCT00822679 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00822679 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00822679 about?
NCT00822679 is a clinical study titled "Eszopiclone and Inflammatory Mediators in Patients With Acute Coronary Syndrome". The purpose of the study is to examine the effects of Eszopiclone, a sleep aid, on inflammatory mediators and coagulability in patients with a recent myocardial infarction.
What is the current status of trial NCT00822679?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2007-10. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00822679?
The interventions under investigation include: Placebo (OTHER), Eszopiclone (DRUG).
Who is sponsoring clinical trial NCT00822679?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00822679's enrollment target sits among peer trials
5 1989th of 2000 higher than 7 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia